

Article title: The Effectiveness and Safety of Gemcitabine plus Nab-paclitaxel in Elderly Patients
with Advanced Pancreatic Cancer: A Single-Center Retrospective Cohort Study

Journal name: Investigational New Drugs

Sae Ohwada, Akiko Todaka, Hiroshi Nakase, Hiromichi Shirasu, Takeshi Kawakami, Satoshi
Hamauchi, Takahiro Tsushima, Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Kentaro Yamazaki

Corresponding Author:

Kentaro Yamazaki

Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumicho, Suntougun, Shizuoka

411-8777, Japan

E-mail: k.yamazaki@scchr.jp

Online Resource 1. Kaplan-Meier estimates time to deterioration by ECOG PS levels according to

(a) treatment and (b) treatment and baseline PS

GnP, gemcitabine (GEM) plus nab-paclitaxel; Monotherapy (GEM or S-1); ECOG PS, Eastern

Cooperative Oncology Group performance status

